Do GLP-1 patches work?

No. A patch cannot deliver a GLP-1 receptor agonist through intact skin, because the molecule is far too large to cross it. Semaglutide weighs about 4,114 Daltons and the established upper limit for passive skin penetration is around 500 Daltons, so it is roughly 8 times too heavy. For comparison, nicotine — which transdermal patches genuinely do deliver — weighs 162. This is a physical limit rather than a regulatory gap, which is why no approved GLP-1 patch exists anywhere.

Are GLP-1 patches safe?

A patch containing no active drug is unlikely to cause direct harm beyond skin irritation. The meaningful risk is different: someone who believes they are treating a medical condition may spend months on a product that does nothing, and delay treatment that works. A separate and much more serious category is unapproved semaglutide sold as a liquid or powder labelled 'for research purposes only' while supplying dosing instructions — the FDA has issued warning letters over exactly that.

What is actually in a GLP-1 patch?

We have not laboratory-tested any product, but the category divides into three groups: herbal or botanical patches marketed for metabolism, acupressure stickers that do not claim to deliver a drug at all, and topical 'peptide' products whose name implies the real thing. None delivers a GLP-1 receptor agonist. If a product can be bought without a prescription, it is not a GLP-1 medication.

Why do GLP-1 patch reviews describe weight loss?

Because people who buy a weight-loss product usually change something else at the same time, and a patch applied daily is an effective reminder to keep doing it. The weight loss can be entirely real while the patch contributes nothing to it. That effect belongs to the person rather than the product.

Delivery formats

Is there a GLP-1 patch?

Evidence-sourced

Written and fact-checked to our published editorial standards.Last updated 2026-08-27. Every clinical claim on this page is sourced to a named primary authority, listed at the foot of the page — see how we research, source, and correct our work.

Direct answer

What you need to know

Evidence strength: Strong

No. There is no FDA-approved transdermal GLP-1 patch, and this is not a gap waiting to be filled — it is a chemistry problem. Semaglutide has a molecular weight of about 4,113.58 Daltons. The long-established upper limit for a molecule passively crossing intact skin is around 500 Daltons. Semaglutide is roughly 8 times too large. Products sold as “GLP-1 patches” contain no GLP-1 receptor agonist.

Key takeaways

No GLP-1 receptor agonist is approved in any transdermal form, in any country we could verify.
The barrier is molecular size, not regulatory delay.
Patches sold under this name are typically herbal or “acupressure” products, not medicines.
If you can buy it without a prescription, it is not a GLP-1 drug.

Important limitation: Research into enhanced transdermal peptide delivery — microneedles, iontophoresis, chemical permeation enhancers — is a real scientific field. Nothing in it has produced an approved GLP-1 patch, and none of it applies to a sticker you can buy online today.

Next action: If you want a non-injectable option, the real one is an oral tablet — see the format comparison — and it requires a prescription. Discuss it with a licensed prescriber.

Primary sources: Bos JD, Meinardi MM — Experimental Dermatology, 2000 (PMID 10839713), U.S. Food & Drug Administration, DailyMed, U.S. National Library of Medicine, U.S. Food & Drug Administration

General education, not medical advice. This page is not a review of any specific product.

Why the size problem is decisive

Transdermal patches are a genuine, well-established delivery route — for the right molecules. Nicotine works in a patch because nicotine is small: about 162 Daltons. The outermost layer of skin, the stratum corneum, is an effective barrier, and the practical threshold for getting through it passively has been put at roughly 500 Daltons since Bos and Meinardi’s 2000 review.

Nicotine is small enough to cross intact skin on its own, which is why a nicotine patch works. Semaglutide is not, by a wide margin — it sits on the barrier rather than passing through it.Threshold from Bos & Meinardi, Experimental Dermatology, 2000. Circle diameter is proportional to the cube root of molecular weight, so the three are comparable as objects rather than as numbers.

The same three figures as numbers. Semaglutide is a 31-amino-acid peptide; nicotine is a small alkaloid.
Molecule	Molecular weight	Crosses intact skin passively?
Nicotine	~162 Da	Yes — well under the limit, and patches are approved
Practical thresholdBos & Meinardi, 2000	~500 Da	The upper bound
Semaglutide	~4,113.58 Da	No — about 8× over the limit

This is the rare case where you do not have to weigh competing studies. A molecule that size does not cross intact skin on its own, and no amount of marketing changes the number.

So what is actually in the patches being sold?

We have not laboratory-tested any product, and we are not naming or reviewing specific brands. But the category divides fairly cleanly:

Herbal or botanical patches
Marketed for “metabolism” or “belly fat,” containing plant extracts. Whatever their merits, they are not delivering a GLP-1 receptor agonist, and the same size barrier applies to most of their ingredients too.
Acupressure or acupoint stickers
These do not claim to deliver a drug at all. They are placed on the body rather than absorbed, and their marketing usually borrows the GLP-1 name without asserting the molecule is present.
“Peptide” topical products
The most misleading group, because the word peptide implies the real thing. A peptide in a cream or patch faces exactly the barrier described above. Presence in the product is not the same as delivery into the bloodstream.

The same reasoning applies one shelf over. Liquid drops sold as GLP-1 supplements face the identical barrier for the identical reason, and are the format most often confused with the approved oral tablets, which are a genuinely different thing.

The version of this that is genuinely dangerous

Some sellers offer unapproved semaglutide as a liquid or powder labelled “for research purposes only” or “not for human consumption,” while supplying dosing instructions. The FDA has issued warning letters over exactly this. These products are not reviewed for identity, purity, sterility, or strength, and the agency has also documented fraudulent compounded products whose labels name pharmacies that do not exist.

A “research use only” label is not a technicality to work around. It is the seller stating the product was never intended to go into a person.

Do GLP-1 patches have side effects?

This is asked often, and the honest answer has an unexpected shape: there is no side-effect profile for these products, because nobody is required to produce one. An approved medicine has a labelled adverse-reaction table because trials counted events against a placebo arm and a regulator reviewed the result. A patch sold as a supplement or a cosmetic has been through none of that, so “no reported side effects” on a product page means no one collected reports — not that nothing happens.

What can be said follows from what the product is rather than from any study of it. Three things are worth knowing:

The GLP-1 side effects do not apply. Nausea, delayed stomach emptying and the rest come from the drug acting on receptors it never reaches here. A patch that delivers no GLP-1 receptor agonist cannot produce them — which is the same fact that means it cannot produce the intended effect either.
Adhesive and botanical skin reactions are the real category. Contact dermatitis from adhesives and plant extracts is ordinary and well described in dermatology, and it is what a patch worn for hours can plausibly cause.
Undisclosed ingredients are the genuine unknown. Supplement labelling is not verified before sale, and the FDA has repeatedly found weight-loss products containing pharmaceutical ingredients not named on the label. That risk is unquantified here, and saying so is more accurate than assigning it a number.

The largest risk is not on this list, because it is not a side effect. It is the months spent on something inert by someone who had decided to treat a medical condition.

What to make of the reviews

Reviews of these patches often describe genuine weight loss, and there is no need to assume anyone is lying. People who buy a weight-loss product generally change something else at the same time — eating less, moving more, watching intake more closely — and a product worn on the body every day is an unusually effective daily reminder to do those things. That effect is real, it belongs to the person rather than the patch, and it is available for free.

Several patches are also sold under brand names that appear in searches alongside this one. We have not tested any of them and do not review specific products, but the physical argument above is not brand-specific: it follows from the size of the molecule, so it applies identically to every patch claiming to deliver one.

What to do if you want to avoid injections

This is a completely reasonable thing to want, and there is a real answer to it, though it starts with a prescription rather than a purchase — the sequence for getting one legitimately sets out why that step comes first. Three oral GLP-1 medications are now FDA-approved: Rybelsus and Wegovy tablets (both oral semaglutide) and Foundayo (orforglipron), approved in April 2026. All three require a prescription. See how the formats compare, or how these medications work for the underlying mechanism.

Common questions

Do GLP-1 patches work?: No. A patch cannot deliver a GLP-1 receptor agonist through intact skin, because the molecule is far too large to cross it. Semaglutide weighs about 4,114 Daltons and the established upper limit for passive skin penetration is around 500 Daltons, so it is roughly 8 times too heavy. For comparison, nicotine — which transdermal patches genuinely do deliver — weighs 162. This is a physical limit rather than a regulatory gap, which is why no approved GLP-1 patch exists anywhere.
Do GLP-1 patches have side effects?: There is no established side-effect profile, because these products are not regulated as medicines and nobody is required to collect one. The side effects associated with GLP-1 medications — nausea, delayed gastric emptying — cannot occur, since no GLP-1 drug reaches the bloodstream. The plausible effects are skin reactions to adhesives or botanical ingredients, and the genuine unknown is undisclosed ingredients, since supplement labels are not verified before sale.
Are GLP-1 patches safe?: A patch containing no active drug is unlikely to cause direct harm beyond skin irritation. The meaningful risk is different: someone who believes they are treating a medical condition may spend months on a product that does nothing, and delay treatment that works. A separate and much more serious category is unapproved semaglutide sold as a liquid or powder labelled 'for research purposes only' while supplying dosing instructions — the FDA has issued warning letters over exactly that.
What is actually in a GLP-1 patch?: We have not laboratory-tested any product, but the category divides into three groups: herbal or botanical patches marketed for metabolism, acupressure stickers that do not claim to deliver a drug at all, and topical 'peptide' products whose name implies the real thing. None delivers a GLP-1 receptor agonist. If a product can be bought without a prescription, it is not a GLP-1 medication.
Why do GLP-1 patch reviews describe weight loss?: Because people who buy a weight-loss product usually change something else at the same time, and a patch applied daily is an effective reminder to keep doing it. The weight loss can be entirely real while the patch contributes nothing to it. That effect belongs to the person rather than the product.
Is there any non-injectable GLP-1?: Yes, but it is a tablet rather than a patch. Three oral GLP-1 medications are FDA-approved: Rybelsus and Wegovy tablets, both oral semaglutide, and Foundayo (orforglipron), approved in April 2026. All three require a prescription.

Sources

Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.

The 500 Dalton rule for the skin penetration of chemical compounds and drugsBos JD, Meinardi MM — Experimental Dermatology, 2000 (PMID 10839713)Supports: The ~500 Dalton upper limit for passive penetration of intact skin, which semaglutide exceeds several times over.
FDA intends to take action against non-FDA-approved GLP-1 drugsU.S. Food & Drug AdministrationSupports: FDA's position on unapproved GLP-1 products sold direct to consumers, including those labelled for research use.
FDA-approved prescribing information (drug labels)DailyMed, U.S. National Library of MedicineSupports: The approved dosage forms for every semaglutide and tirzepatide product — all injection or oral tablet.
Drug approvals, labeling and safety communicationsU.S. Food & Drug AdministrationSupports: Approval status and dosage form, checkable in Drugs@FDA and the Orange Book.

This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.